Dernek Hakkında Tıbbi Onkoloji Derneği Haberler

ESMO'dan Gelen Duyuru

Early Braest cancer survey


ESMO and Jules Bordet Institute Collaborative Survey on 'Controversial Issues in Early Stage Breast Cancer'


Dear colleague,

Early stage breast cancer represents one dynamically-evolving field of medical oncology, with an ever-growing understanding of the biological background of the disease. This, along with technological advances, empowers the development of improved diagnostic and therapeutic modalities.






Survey: 'Controversial Issues in Early Stage Breast Cancer'

ESMO in collaboration with the Jules Bordet Institute (Brussels, Belgium), an Integrated Multidisciplinary Cancer Center, are conducting this survey entitled 'Controversial Issues in Early Stage Breast Cancer '.


  Please take the survey now

Deadline: 30 November


This fifteen-minute survey will explore the current clinical practice in the management of early-stage breast cancer patients, identifying areas of controversies and exploring how you implement newest advances. By participating in this survey, you will help us generate educational tools ?tailored? to your needs. The final goal is the optimization of the treatment of early-stage breast cancer patients.

On behalf of ESMO I thank you in advance for your valuable participation.

Prof. Martine Piccart, MD, PhD
ESMO President 2012-2013

Note: If you have previously completed this questionnaire, please do not complete it again. Your replies will be confidential.








ESMO Pocket Guidelines

Direct access to

· Journal Club · Membership · Guidelines · E-Learning · Fellowship offers

You are receiving this email because you are an ESMO Member or attended the IMPAKT Breast Cancer Congress. ESMO does not endorse any product, therapy or position mentioned in this email or in subsequent links to new articles. The information contained within should not be construed as medical advice.